Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use in Children 4 years and aboveAzithromycin
Use in Children 4 years and overClarithromycin
History of QT prolongation; known history of cardiac and cerebrovascular events.
Colloidal ciprofloxacin equivalent: 50 mg.
Pregnant women, lactating women, women trying to conceive, and women taking other medications should consult a healthcare professional before use. Ciprofloxacin is present in other medications. Consult your doctor for more details.
Special precautions for use w/ food: not more than 10 days prior to symptoms to minimise GI discomfort. Avoid contact with eyes.
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, and lower seizure threshold; history or risk factors for QT prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g.
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Use on meds goDairy
This study compared ciprofloxacin (Cipro) with a combination of ciprofloxacin (Cipro) with trimethoprim/sulfamethoxazole (Sulfamethoxazole) in the treatment of women with acute pelvic inflammatory disease (PID) and for a 6-month period in women who have had pelvic inflammatory disease (PID) in the absence of urinary tract symptoms or who have had pelvic inflammatory disease (PID) in the presence of sexual intercourse. The study was a randomized, double-blind, placebo-controlled, fixed-dose, parallel group, placebo-controlled, parallel group, parallel group, controlled-sex, parallel group, fixed-dose, open-label, double-blind, randomised, double-masked study that enrolled women with PID in the absence of urinary symptoms. The study was approved by the Research Ethics Committee (reference number: 2-23). All participants provided written informed consent. The trial was registered with the New Zealand International Urological Association (NIIRA) and was conducted in the New Zealand Clinical Trials Registry (NCT0186787).
Figure 1 The diagram displays the protocol. *Inclusion criteria:* PID of ≥ 6 months. *PID:* PID in the absence of sexual intercourse. *PIDin the presenceof urinary tract symptoms.in the absenceof sexual intercourse:* PID in the presence of urinary tract symptoms or intercourse in the absence of sexual intercourse.of sexual intercourse:* PID in the absence of sexual intercourse.of sexual intercourse:* PID in the presence of sexual intercourse.Sold and Supplied by Healthylife Pharmacy
This product is a Prescription Only Medicine (S4) and is sold by Healthylife Pharmacy, an independently owned and operated pharmacy business. This prescription product requires a valid Australian script.
Medicare CardNo MedicareConcession
$19.95
Healthylife provides general product information such as nutritional information, country of origin and product packaging for your convenience. This information is intended as a guide only, including because products change from time to time. Please read product labels before consuming. For therapeutic goods, always read the label and follow the directions for use on pack. If you require specific information to assist with your purchasing decision, we recommend that you contact the manufacturer via the contact details on the packaging or email us at [email protected]. Product ratings and reviews are taken from various sources including Bazaarvoice. Healthylife does not represent or warrant the accuracy of any statements, claims or opinions made in product ratings and reviews.
HealthylifeProduct Name: Ciproxin T 500/250mg Tablet US Brand: Ciproxin; Length of Action: 250mg / 250mg Tablet Benefits: Effective Treatment for Bacterial Infections: Ciproxin is a powerful antibiotic that can effectively combat various types of bacterial infections, such as respiratory tract infections, urinary tract infections, skin infections, and soft tissue infections. It can also be prescribed for other types of infections such as sinusitis, urinary tract infections, tonsillitis, and skin infections.
Healthylife Pharmacy, Inc. is a health food and drug marketplace thatoshouldyouconsultHealthylife provides product information like price, availability, and more. If you have any concerns about a particular product, please contact us via the contact details on the packaging or email us at [email protected]. Prescription Only
Healthylife acknowledges theLegal WARNING
HealthylifeDiscountedHealthylife provides product information like price, availability, and more. If you have any concerns about a particular product, please contact Healthylife via the contact details on the packaging or email us at [email protected].
Healthylife supplies generic versions of Ciproxin T 500/250mg Tablets in the United States, Europe and most other countries. Healthylife requires a prescription only if you have taken Ciproxin T 500/250mg Tablets since December 31, 2013. If you have any questions about a particular product, please contact Healthylife at [email protected].
Treatment of bacterial infections of the lungs, nose, ear, bones and joints, skin and soft tissue, kidney, bladder, abdomen, and genitals caused by ciprofloxacin-susceptible organisms. Infections may include urinary tract infection, prostatitis, lower respiratory tract infection, otitis media (middle ear infection), sinusitis, skin, bone and joint infections, infectious diarrhea, typhoid fever, and gonorrhea.
May be taken with or without food. May be taken w/ meals to minimise GI discomfort. Do not take w/ antacids, Fe or dairy products.
Hypersensitivity to ciprofloxacin or other quinolones. History or risk of QT prolongation; known history of myasthenia gravis. Concomitant use with tizanidine.
Vomiting, Stomach pain, Nausea, Diarrhea
Patient with known or suspected CNS disorders, risk factors predisposing to seizures, or lower seizure threshold; history or risk factors for QT interval prolongation, torsades de pointes, uncorrected hypokalaemia/hypomagnesaemia, cardiac disease (e.g. heart failure, MI, bradycardia); positive family history of aneurysm disease, pre-existing aortic aneurysm or dissection and its risk factors (e.g. Marfan syndrome, vascular Ehlers-Danlos syndrome, hypertension, peripheral atherosclerotic vascular disease); diabetes, previous tendon disorder (e.g. rheumatoid arthritis), G6PD deficiency. Renal and hepatic impairment. Elderly, children. Pregnancy and lactation.
Store between 20-25°C.
Quinolones
Hospitalities in or around Manila are 963+64�57.| Active ingredient | Dosage |
|---|---|
| Ciprofloxacin | 250 mg |
Use in adolescents
For use in severe sinusitisUse in adolescents aged 14-17 years
| MedsGo Class 2 | 250 mg/100 mL |
Use in severe dehydration (e.g. alkalosis, alkali hydroxam/metronidazole, blood-clotting disorder, electrolyte imbalance, electrolyte disturbance)
Use in severe infections (see Precautions)
Interaction with other medicinal productsActive ingredient(s)
ciprofloxacin (as ciprofloxacin), quinolones (e.g. quinolone antibiotics); antibacterial
Potentiates the effects of ciprofloxacin.Ciprofloxacin may be metabolised by cytochrome P450 (CYP) isoforms 3A4 (major route) and 4A (minor route) in humans and in some other types of organisms.CYP isoforms 3A4 is primarily catalase enzyme; the other isoforms are metabolisers (enzyme modulators).CYP isoforms 3A4 is predominantly catalase enzyme; the other isoforms are metabolisers (enzyme modulators) and substrate transporters.The presence of active metabolite may lead to adverse effects in patients with cytochrome P450 isoforms inhibitors.CYP isoforms 3A4 and 3A5 are not fully characterized; they are thought to work primarily by interacting with neurotransmitters such as dopamine, serotonin, norepinephrine, epinephrine, and others. The interaction of these 2 isoforms with quinolone antibiotics may lead to a reduction of antibacterial activity.
Stade de France Pharmacy